Nebilet (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic receptor antagonist that slows heart rate and reduces contractility. It also enhances nitric‑oxide release from the endothelium, causing vasodilation. The combined effect lowers peripheral resistance and blood pressure while supporting heart‑failure management.

The appropriate dose of Nebilet is determined by the prescribing clinician based on the individual’s blood‑pressure readings, heart‑failure status, renal function, and other medical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Nebivolol is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used if the potential benefit justifies the potential risk. Limited data are available for breastfeeding, so a healthcare professional should evaluate the risk‑benefit ratio.

To order Nebilet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older non‑selective β‑blockers, nebivolol offers additional nitric‑oxide‑mediated vasodilation, which can improve endothelial function and cause fewer metabolic side effects. It is often chosen for patients who need both blood‑pressure control and heart‑failure benefit, whereas ACE inhibitors or calcium‑channel blockers may be preferred when renal protection is a priority.

Nebilet tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiry date printed on the packaging.

Nebilet is taken orally as a whole tablet with a glass of water. It is usually taken once daily, preferably at the same time each day, and should be swallowed whole without crushing or chewing to ensure consistent absorption.

Serious adverse events include severe bradycardia, heart block, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as angio‑edema. Patients should seek immediate medical attention if they experience fainting, extreme fatigue, difficulty breathing, or swelling of the face and throat.

Nebilet is contraindicated in patients with second‑ or third‑degree atrioventricular block, severe bradycardia, sick sinus syndrome without a pacemaker, decompensated heart failure, and those with known hypersensitivity to nebivolol or any excipients. Caution is also advised for individuals with severe asthma or chronic obstructive pulmonary disease.